WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 558685
Description: FCPR16 is a phosphodiesterase 4 (PDE4) inhibitor with little emetic potential, which blocks MPP+ induced oxidative damage in SH-SY5Y cells and neurons via AMPK-dependent autophagy.
MedKoo Cat#: 558685
Chemical Formula: C18H16ClF2NO3
Exact Mass: 367.0787
Molecular Weight: 367.78
Elemental Analysis: C, 58.79; H, 4.39; Cl, 9.64; F, 10.33; N, 3.81; O, 13.05
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: FCPR16; FCPR 16; FCPR-16
IUPAC/Chemical Name: N-(2-Chlorophenyl)-3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzamide
InChi Key: FXJNCIZGQFVQLF-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H16ClF2NO3/c19-13-3-1-2-4-14(13)22-17(23)12-7-8-15(25-18(20)21)16(9-12)24-10-11-5-6-11/h1-4,7-9,11,18H,5-6,10H2,(H,22,23)
SMILES Code: O=C(NC1=CC=CC=C1Cl)C2=CC=C(OC(F)F)C(OCC3CC3)=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 367.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Tang L, Huang C, Zhong J, He J, Guo J, Liu M, Xu JP, Wang HT, Zhou ZZ. Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect. Eur J Med Chem. 2019 Apr 15;168:221-231. doi: 10.1016/j.ejmech.2019.02.026. Epub 2019 Feb 11. PubMed PMID: 30822711.
2: Zhong J, Xie J, Xiao J, Li D, Xu B, Wang X, Wen H, Zhou Z, Cheng Y, Xu J, Wang H. Inhibition of PDE4 by FCPR16 induces AMPK-dependent autophagy and confers neuroprotection in SH-SY5Y cells and neurons exposed to MPP(+)-induced oxidative insult. Free Radic Biol Med. 2019 May 1;135:87-101. doi: 10.1016/j.freeradbiomed.2019.02.027. Epub 2019 Feb 25. PubMed PMID: 30818055.
3: Zhong Q, Yu H, Huang C, Zhong J, Wang H, Xu J, Cheng Y. FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 2;90:62-75. doi: 10.1016/j.pnpbp.2018.10.017. Epub 2018 Nov 1. PubMed PMID: 30391306.
4: Zhong J, Yu H, Huang C, Zhong Q, Chen Y, Xie J, Zhou Z, Xu J, Wang H. Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP(+)-induced decline of mitochondrial membrane potential and oxidative stress. Redox Biol. 2018 Jun;16:47-58. doi: 10.1016/j.redox.2018.02.008. Epub 2018 Feb 14. PubMed PMID: 29475134; PubMed Central PMCID: PMC5842311.
5: Chen J, Yu H, Zhong J, Feng H, Wang H, Cheng Y, Zou Z, Huang C, Zhou Z, Zheng W, Xu J. The phosphodiesterase-4 inhibitor, FCPR16, attenuates ischemia-reperfusion injury in rats subjected to middle cerebral artery occlusion and reperfusion. Brain Res Bull. 2018 Mar;137:98-106. doi: 10.1016/j.brainresbull.2017.11.010. Epub 2017 Nov 16. PubMed PMID: 29155261.